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We reported evidence of bradykinin (BK) regeneration from C-terminal extended BK
sequences that behave as peptidase-activated B2 receptor (B2R) agonists. Further
to these in vitro studies, we carried out in vivo experiments to verify hemodynamic
effects of BK analogs exhibiting variable susceptibility toward vascular and blood plasma
peptidases. Rats were anesthetized and instrumented to record blood pressure and
heart rate responses to bolus intravenous (i.v.) injection of increasing doses of BK,
B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-BK), BK-Arg, BK-His-Leu or BK-Ala-Pro, in the
absence or presence of specific inhibitors. In some experiments, pulsed Doppler flow
probes measured hindquarter Doppler shift in response to i.v. injections of kinins.
BK caused rapid, transient and dose-related hypotensive effects. These effects were
potentiated ∼15-fold by the angiotensin converting enzyme (ACE) inhibitor, enalaprilat,
but extensively inhibited by icatibant (a B2R antagonist) and not influenced by the
Arg-carboxypeptidase (CP) inhibitor (Plummer’s inhibitor). The hypotensive responses
elicited by the peptidase-resistant B2R agonist, B-9972, were not affected by enalaprilat,
but were inhibited by icatibant. The hypotensive responses to BK-Arg were abolished
by pre-treatment with either the Arg-CP inhibitor or icatibant, pharmacologically
evidencing BK regeneration. The hypotensive effects of BK-His-Leu and BK-Ala-Pro,
previously reported as ACE-activated substrates, were abolished by icatibant, but not
by enalaprilat. In vivo regeneration of BK from these two C-terminally extended analogs
with no affinity for the B2R must follow alternative cleavage rules involving unidentified
carboxypeptidase(s) when ACE is blocked. The transient hypotensive responses to BK
and three tested analogs coincided with concomitant vasodilation (increased Doppler
shift signal). Together, these results provide in vivo evidence that interesting hypotensive
and vasodilator effects can be extracted from prodrug peptides that behave as
peptidase-activated B2R agonists.
Keywords: bradykinin, angiotensin converting enzyme, arginine carboxypeptidases, B2 receptors, B-9972,
hypotension, blood flow
INTRODUCTION
Kinins, the bradykinin-related peptides, are blood-derived peptide hormones generated by the
enzymatic action of proteases called kallikreins on kininogen precursors in response to a variety
of physiological and pathological stimuli, including ischemia and tissue injury (Bergaya et al.,
2001; Meneton et al., 2001). Bradykinin (BK), a nine amino-acid vasoactive peptide, exerts a
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large spectrum of actions implicated in many physiological and
pathological processes, such as inﬂammatory reactions, through
its ability to cause vasodilation, hyperemia, vascular leakage,
and pain sensation (Leeb-Lundberg et al., 2005; Moreau et al.,
2005). BK plays also an important role in the regulation of
blood pressure, renal, and cardiac functions, via its ability
to activate vascular endothelial cells leading to vasodilation,
tissue-type plasminogen (t-PA) release, production of nitric
oxide (NO) and mobilization of arachidonic acid (Brown et al.,
2000; Moreau et al., 2005). The availability of transgenic and
knock out animal models for BK-synthesizing or -catabolic
enzymes or BK receptors, as well as parallel experiments with
pharmacological receptor antagonists in a variety of species,
have strengthened the evidence that BK has cardiac and renal
protective roles (Yang et al., 1997; Bascands et al., 2003; Griol-
Charhbili et al., 2005; Kakoki et al., 2007; Xi et al., 2008). BK
exerts its biologic eﬀects by selective activation of two distinct
G protein coupled receptors termed BK B2 and B1 receptors
(B2R, B1R). The B2R is constitutively expressed in many tissues,
and its activation is believed to play a major role in the
cardioprotective eﬀects of BK during hypertension and other
clinical and experimental conditions, such as cardiac failure,
ischemia, myocardial infarction, and pulmonary hypertension
(Heitsch, 2003; Veeravalli and Akula, 2004; Xi et al., 2008;
Marketou et al., 2010; Sharma and Al-Banoon, 2012; Potier
et al., 2013). Vasodilation and endothelial release of NO and tPA
are examples of potentially salutary eﬀects mainly concerning
kinins and the endothelial cell B2Rs (Pretorius et al., 2003;
Leeb-Lundberg et al., 2005). In contrast, the B1R appears to
have limited distribution and is generally absent in healthy
mammalian tissues, but is strongly inducible within few hours
under conditions of inﬂammation and tissue damage (Marceau
et al., 1998; Leeb-Lundberg et al., 2005).
BK has a very short half-life (<15 s, Linder et al., 1990)
being rapidly inactivated in circulation by non-speciﬁc exo- or
endopeptidases, commonly referred to as kininases. The kininase
I category now includes various arginine-carboxypeptidases
(carboxypeptidases N, M, possibly D) that produce des-Arg9-
BK from BK; this rather minor metabolic pathway is, however,
important because it produces the optimal agonists of the
B1Rs (Cyr et al., 2001). Kininase II, identical to angiotensin
I-converting enzyme (ACE), is present in plasma and vascular
endothelial cells throughout the body. It inactivates kinins
by initially removing the C-terminal dipeptide Phe-Arg from
the substrate. ACE inhibitors are widely used in the therapy
of cardiovascular and renal diseases (Izzo and Weir, 2011).
Although the cardioprotective eﬀects of ACE inhibition have
been mostly attributed to inhibition of the formation of the
vasopressor agent angiotensin II, growing body of evidence
obtained in humans and animal models indicates that a fraction
of the therapeutic eﬀects of ACE inhibition is mediated by
endogenous kinins, especially at the level of preformed and
widely expressed B2Rs (Gainer et al., 1998; Squire et al., 2000;
Pretorius et al., 2003; Leeb-Lundberg et al., 2005; Marketou et al.,
2010).
Although there have been very few attempts to use BK or a
derivative in pharmacotherapy, the cardiovascular beneﬁts of B2R
agonists were investigated in rodent models where side eﬀects
were not really addressed (Taraseviciene-Stewart et al., 2005;
Marketou et al., 2010; Potier et al., 2013). Nevertheless, results
were impressive with alleviation of pulmonary hypertension
and its cardiac complications (Taraseviciene-Stewart et al.,
2005), reduction in acute myocardial damage following ischemia
and reperfusion and of ﬁbrotic long term complications of
myocardial infarction (Marketou et al., 2010; Potier et al.,
2013). All these eﬀects are postulated to stem from BK-induced
endothelium-mediated vasodilation, mainly by stimulation of
B2Rs. Consequently, B2R agonists may have important clinical
value in the treatment and prevention of various cardiovascular
disorders such as hypertension, ischaemic heart disease and other,
by mimicking the reported beneﬁcial eﬀects of BK (Heitsch,
2003). Inspired by a “prodrug” strategy where a therapeutic B2R
agonist would be activated only at the level of vascular endothelial
cells, this laboratory recently provided pharmacological evidence
of BK regeneration from extended sequences that behave as
peptidase-activated B2R agonists (Charest-Morin et al., 2014). In
continuity with this work, we undertook the present in vivo study
in healthy rats to assess the feasibility of extracting beneﬁcial
vascular eﬀects of stimulation of endothelial B2Rs using a variety
of ligand design strategies that mainly exploit the susceptibility
of these ligands (peptidase-resistant B2R agonists and “prodrug”
peptides extended around the BK sequence) toward resident
vascular peptidases. The BK-related peptides tested and their
hypothetical metabolism are presented in Figure 1. The natural
BK sequence was compared to the peptidase-resistant agonist, B-
9972, and to C-terminally prolonged BK homologs designed to
retain little aﬃnity for the B2R (Table 1), but that are presumably
activated by vascular or blood plasma peptidases, such as ACE
(e.g., BK-His-Leu and BK-Ala-Pro with good aﬃnity for ACE,
Table 1) or arginine carboxypeptidases (BK-Arg).
MATERIALS AND METHODS
Experimental Animals and Care
All experimental methods and animal care procedures were
reviewed and approved by the Animal Care and Handling
Committee of Laval University, in accordance with the Canadian
Council on Animal Care. Experiments were performed on male
Sprague-Dawley rats (300–375 g) purchased from Charles River
Laboratories (St-Constant, QC, Canada). The rats were housed
two per cage in a temperature-controlled room (22 ± 1◦C) on
a 12:12-h light-dark cycle (lights on at 0600). Animals had free
access to normal chow diet and tap water. They were allowed to
acclimate to their environmental conditions for 1 week prior to
being studied.
[3H]Enalaprilat Binding Competition
Assay
The aﬃnity of BK and its analogs for ACE has been previously
estimated using the displacement of [3H]enalaprilat binding to
the enzyme expressed in cells (summarized in Table 1), except for
BK-Arg. To compare the aﬃnity of BK-Arg to that of BK for ACE,
HEK 293a cells that transiently expressed human recombinant
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FIGURE 1 | Previously described BK-related peptides tested in vivo as
B2R agonists in the present study. BK is a direct high affinity agonist
(marker 1) that is intrinsically fragile, being degraded by several peptidases
that terminate its signaling (some mentioned, marker 2). B-9972 is an
inactivation-resistant agonist of the B2R by virtue of several of its non-natural
residues (marker 3). Extended BK sequences as potential “prodrug” agonists
of the B2R activated peptidases were also tested (markers 4, 5). Icatibant, a
peptide antagonist of the B2R, is a further direct ligand of the receptor (marker
6). The structure of peptidase-specific inhibitors exploited in the present study
and their putative binding mode to the active sites of Arg-CP (Plummer’s
inhibitor) or ACE (enalaprilat) are indicated (representation modified from
Ondetti et al., 1977). Abbreviations: ACE, angiotensin converting enzyme;
APP, aminopeptidase P; Arg-CP, arginine carboxypeptidase.
ACE C-terminally fused with the mCherry ﬂuorescent protein
were used to perform a [3H]enalaprilat binding assay as described
(Koumbadinga et al., 2010) (the ACE variant construction retains
its high aﬃnity for the radioligand; Charest-Morin and Marceau,
in preparation). A 2 nM concentration of [3H]enalaprilat was
used to generate binding competition curves.
Surgical Preparation
At the end of the acclimation period, the rats were anesthetized
with sodium pentobarbital (50 mg kg−1, i.p., supplemented as
required) and had two separate catheters implanted; one into the
right jugular vein [for intravenous ( i.v.) injection] and the other
into the left femoral artery (for direct measurement of blood
pressure and heart rate (HR). In some experiments, a pulsed
Doppler ﬂow probe (Haywood et al., 1981) was also implanted
around the distal abdominal aorta (below the ileocecal artery)
through a midline abdominal incision to monitor changes in
hindquarter hemodynamic, according to the method developed
by Gardiner and Bennett (1988) and as previously described
(Bachelard et al., 1992b). The probes wires were connected to
a pulsed Doppler monitoring system (VF-1 Doppler ﬂowmeter;
Crystal Biotech, Holliston, MA, USA) modiﬁed to operate with
a pulse repetition frequency of 125 kHz (Gardiner et al., 1990)
and ﬁtted with HVPD-20 modules. The mean Doppler signal
represents the average hindquarter blood ﬂow velocity, a relative
index of blood ﬂow. The accuracy of the pulsed Doppler
method in detecting changes in regional blood ﬂow and vascular
resistance was established by the demonstration of a signiﬁcant
correlation between velocity recorded from the Doppler unit and
volume ﬂow recorded simultaneously (Haywood et al., 1981).
Experiments started at least 30 min following the end of surgery
in anesthetized rats.
Blood Pressure and Heart Rate
Measurements
The femoral arterial catheter implanted to monitor direct
blood pressure was connected to a pressure transducer (TSD
104A, Biopac Systems Inc., Goleta, CA, USA) coupled to a
computer-based data acquisition system (MP100, Biopac Systems
Inc., Goleta, CA, USA) to continuously record pulsate arterial
pressure. The animals were maintained under anesthesia and
were warmed with a heated pad. The mean arterial pressure and
HR were simultaneously calculated by the Acknowledge software
(version 3.9.1) for Windows (Biopac Systems Inc., Goleta, CA,
USA) and displayed continuously.
In Vivo Vascular Reactivity
The experiments were initiated after allowing at least 20 min
for stabilization. Then, baseline measurements of HR and phasic
and mean arterial blood pressure (MAP) were made over a
period of 10 min. A dose response curve was then obtained
by recording changes in blood pressure and HR elicited by
i.v. injection of peptide vehicle followed by increasing doses
(0.025, 0.1, 0.4, 1.6 et 6.4 µg/kg) of one of these peptides:
BK, BK-His-Leu, B-9972, BK-Arg, BK-Ala-Pro or des-Arg9-
BK. Peptides were dissolved in isotonic saline (0.9% NaCl)
containing 0.1% BSA to prevent the adsorption of peptide to
the glassware and plastic surfaces. All i.v. injections were given
as 100 µl boluses which were washed in with a further 100 µl
of saline (the dead space of the catheter). Only one peptide
was tested per group of rats and each injection started with
saline-BSA 0.1% followed by the lowest dose of peptide. The
next dose was administered once all recorded cardiovascular
parameters had returned to baseline after the previous injection
(usually 2–10 min). At the end of the experiments each animal
was euthanized with an overdose of sodium pentobarbitone
(240 mg/kg, i.v.).
The mechanism subserving the cardiovascular responses to
i.v. injections of increasing doses of the diﬀerent BK agonists was
ﬁrst investigated in animals pretreated with the ACE inhibitor,
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TABLE 1 | In vitro pharmacology of selected B2R agonists or BK homologs with C-terminal extensions established in radioligand binding competition
assays.
Unlabeled competitor [3H]BK binding to recombinant B2R-GFP [3H]enalaprilat binding to recombinant ACE
Relative potency of competitors Reference Relative potency of competitors Reference
BK 100 100
B-9972 14.3 Bawolak et al., 2007 0.9a Koumbadinga et al., 2010
BK-Arg 3.47 Charest-Morin et al., 2014 9.6 Present Figure 5C
BK-His-Leu 0.3 Charest-Morin et al., 2014 29.5 Charest-Morin et al., 2014
BK-Ala-Pro 0.2 Charest-Morin et al., 2014 44.7 Charest-Morin et al., 2014
abinding to ACE naturally expressed in HUVECs.
enalaprilat. In these experiments, the animals were separated
in ﬁve groups depending on the agonist tested. Enalaprilat was
intravenously administered as bolus (0.1 mg/kg, 0.1 ml) following
a 10 min period of baseline measurements of HR and blood
pressure. Fifteen minutes later, dose-response curves to BK, BK-
His-Leu, B-9972, BK-Arg, or BK-Ala-Pro were obtained in the
indicated group of rats, as described above. Further experiments
were made in rats pretreated with the Plummer’s inhibitor
(mercaptomethyl- 3-guanidinoethylthiopropanoic acid), a high
aﬃnity inhibitor of arginine carboxypeptidases that is an arginine
analog (Plummer and Ryan, 1981). In these experiments, the
inhibitor was intravenously administered as bolus (0.75 mg/kg,
0.1 ml) followed 15 min later by the i.v. injection of increasing
doses of BK or BK-Arg, in two diﬀerent groups of rats. Further
dose-response curves were also obtained from rats pretreated
with a potent, long acting and selective B2R antagonist, icatibant
(Hoe 140) (D-Arg-[Hyp3, Thi5, D-Tic7, Oic8] bradykinin) (Hock
et al., 1991; Wirth et al., 1991; Rhaleb et al., 1992; Marceau
et al., 1994). In these experiments, icatibant was intravenously
administered as bolus (10 µg/kg, 0.1 ml) 15 min before the
i.v. injection of increasing doses of BK, BK-His-Leu, B-9972,
BK-Ala-Pro, or BK-Arg, in separated groups of rats, as above.
The doses of diﬀerent inhibitors were based on preliminary
experiments and from studies performed by others (Ishida
et al., 1989; Wirth et al., 1991; Muto et al., 2003), with
deliberate low dosing for peptidase inhibitors for the sake
of their selectivity of action. Whether a component of BK
hemodynamic eﬀects is mediated by the B1R was assessed
in rats pre-treated with the speciﬁc B1R antagonist, B-9858
(20µg/kg, 0.1ml). B-9858 (Lys-Lys-[Hyp3, Igl5, D-Igl7, Oic8]des-
Arg9-BK) is a selective B1R antagonist (Leeb-Lundberg et al.,
2005) that has been found active at the rat B1R (Scott et al.,
2003).
Acute Hindquarter Hemodynamic Effects
in Anesthetized Rats
Before each experiment, a 30-min stabilization period was
allowed, during which continuous recording of instantaneous
HR, phasic, and MAP and phasic and mean Doppler shift signals
from the hindquarter probe were made in anesthetized rats,
using the Biopac data acquisition and analysis system described
above. The purpose of recording phasic Doppler shift signals
was to ensure that they were of acceptable quality during the
experiments. Then, the rats received i.v. injections of peptide
vehicle (saline-BSA 0.1%), BK (700 ng/kg), B-9972 (150 ng/kg),
BK-Arg (2 µg/kg), and BK-His-Leu (400 ng/kg) in random
order. For each agent, the dose interpolated from the dose-
response curves produces a sizeable hypotensive eﬀect of 15–
30 mmHg. All i.v. injections were given as 100 µl boluses
which were washed in with a further 100 µl of saline. The
next dose was administered once all recorded cardiovascular
parameters had returned to baseline after the previous injection
(usually 5–7 min). At the end of the experiments the rats
were euthanized with an overdose of anesthetic (pentobarbital
240 mg/kg, i.v.).
Drugs
BK and des-Arg9-BK were purchased from Bachem (Torrance,
CA, USA), the B2R antagonist icatibant, from Phoenix
Pharmaceuticals (Burlingame, CA, USA), enalaprilat dehydrate,
from Kemprotec Ltd. (Maltby, Middlesbrough, UK) and the
Plummer’s carboxypeptidase inhibitor, from Calbiochem (La
Jolla, CA, USA). B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-BK)
is a peptidase-resistant agonist of the B2R (Bawolak et al.,
2007, 2009) that was recently resynthesized and puriﬁed by
one of us (L.G.). B-9858 has also been designed, produced
and characterized by us (Larrivée et al., 2000). C-terminally
extended BK sequences (BK-Arg, BK-His-Leu, BK-Ala-Pro)
were custom synthesized and characterized by Peptide 2.0
Inc. (Chantilly, VA, USA) as described (Charest-Morin et al.,
2014).
Statistical Analysis
Data are presented as means ± SEM. Radioligand binding data
were ﬁtted by non-linear regression to a one-site competition
equation using a least-square method (Prism 4.0, GraphPad
Software Inc., San Diego, CA, USA) and IC50 values calculated
from this procedure. Data describing baseline values of HR and
MAP and hypotensive responses to peptides in anesthetized rats
were assessed by using one-way analysis of variance (ANOVA)
followed by the Dunnett’s test (repeated comparison with a
common control). The eﬀects of peptidase inhibitors on the
hypotensive responses to BK and alternate kinin receptor agonists
were assessed by using ANOVA followed by the Dunnett’s test.
A value of P < 0.05 was considered signiﬁcant.
Frontiers in Pharmacology | www.frontiersin.org 4 January 2016 | Volume 6 | Article 306
Jean et al. Bradykinin B2 Receptor Agonist Peptides
RESULTS
Dose Response Effects of BK on Mean
Arterial Blood Pressure and HR
Baseline values for MAP and HR measured in the untreated
control group or 15 min after i.v. pretreatment with enalaprilat,
icatibant or the Plummer’s inhibitor are shown in Table 2.
While no signiﬁcant changes in basal values of MAP were
noted between the enalaprilat and Plummer’s inhibitor
pretreated groups, a slight but signiﬁcant reduction in basal
MAP was found between the icatibant pretreated group
and the control group. Furthermore, slight but signiﬁcant
reductions in basal HR were noted between the icatibant
and Plummer’s inhibitor pretreated groups and the control
group, while a small signiﬁcant increase in basal HR was found
between the enalaprilat pretreated groups and the control
group.
As expected and shown in Figures 2A,B, the i.v. injection
of increasing doses of BK in anesthetized rats caused a
rapid and transient dose-related decrease in MAP; responses
were signiﬁcantly greater than the saline-BSA vehicle for BK
doses superior or equal to 0.4 µg/kg (P < 0.01, Dunnett’s
test). Tachycardia, (preceded by a signiﬁcant bradycardia only
at the dose of 6.4 µg/kg), accompanied the hypotensive
responses only at 0.4 µg/kg and above (Figure 3). In rats
pretreated with enalaprilat, the hypotensive eﬀect of BK
was potentiated ∼15-fold (Figure 2C); the duration of the
hypotensive episodes were not diﬀerent from those of controls
(Figures 2A,B). Pretreatment with icatibant signiﬁcantly and
extensively inhibited the dose-dependent hypotensive response
to BK in the 0.4–6.4 µg/kg dose range (P < 0.01, Dunnett’s
test; Figure 2C), while pretreatment with the Plummer’s inhibitor
had no eﬀect (Figure 2C), consistent with a minor role of
Arg-carboxypeptidases in the metabolism of BK. The B1R
agonist des-Arg9-BK had no signiﬁcant eﬀect on MAP at the
dose of 0.025 µg/kg, while slight but signiﬁcant decreases
in MAP were noted at 0.1 µg/kg and above (P < 0.05,
Dunnett’s test) when compared to vehicle values (Figure 2D).
The comparatively small eﬀects of the fragment des-Arg9-BK
exclude that responses to BK are mediated by the B1Rs via
metabolism by Arg-carboxypeptidases. Accordingly, the B1R
antagonist B-9858, did not signiﬁcantly modify the eﬀect of BK
(Figure 2C).
TABLE 2 | Basal cardiovascular parameters in anesthetized, pre-treated
rats.
Pre-treatment Mean arterial blood
pressure (MAP)
Heart rate (HR) n
Control 103.1 ± 1.8 393 ± 6 47
Enalaprilat 99.2 ± 1.5 416 ± 6∗ 39
Plummer’s inhibitor 107.1 ± 4.7 353 ± 17∗ 12
Icatibant 95.3 ± 1.6∗ 356 ± 8∗∗ 25
B-9858 103.3 ± 6.2 397 ± 11 7
ANOVA F = 3.06, P = 0.011 F = 10.69, P < 10−4
∗P < 0.05; ∗∗P < 0.01, Dunnett’s test vs. Control.
Dose Response Effects of Alternate
Kinin Receptor Agonists on MAP
The i.v. injection of increasing doses of the peptidase-resistant
B2R agonist B-9972 decreased MAP in a dose-dependent manner
(Figures 4A,B). The hypotensive response elicited by B-9972
was signiﬁcant at doses of 0.1 to 6.4 µg/kg when compared
to vehicle values (p < 0.01, Dunnett’s test). The hypotensive
episodes induced by B-9972 had the same temporal proﬁle than
those elicited by BK (Figures 4A and 2A) except for the highest
dose of the analog, that was associated with a half-recovery
time signiﬁcantly longer than that of a similar dose of BK
(P < 0.01, Dunnett’s test). Consistent with its low aﬃnity for
ACE (Table 1) and constrained C-terminal structure, the dose-
dependent hypotensive response to B-9972 was not aﬀected by
pretreatment with enalaprilat. However, consistent with its direct
agonist action on the B2R, the eﬀects of the 0.1–1.6µg/kg doses of
B-9972 were signiﬁcantly abated by pretreatment with icatibant;
thus this competitive antagonist reduced the apparent potency of
B-9972 by about 10-fold (Figure 4B). Biphasic eﬀects of B-9972
on the HR were generally comparable to that of BK but of higher
amplitudes at 1.6–6.4 µg/kg (Figure 3).
As shown in Figures 5A,B, the i.v. injection of increasing
doses of BK-Arg elicited signiﬁcant and dose-dependent
decreases in MAP. The reductions in MAP were signiﬁcant
at doses of 0.4 to 6.4 µg/kg (P < 0.01, Dunnett’s test)
when compared to vehicle values. This peptide is predicted
to be an indirect activator of the B2R, via its conversion
to BK (Figure 1; Table 1). Consistently, its in vivo eﬀects
were abolished in rats pre-treated with either the Plummer’s
carboxypeptidase inhibitor or icatibant (Figure 4B; eﬀects of BK-
Arg 0.4–6.4 µg/kg signiﬁcantly inferior in pretreated animals,
P < 0.05, Dunnett’s test). BK regeneration from BK-Arg should
not involve the carboxydipeptidase ACE (Charest-Morin et al.,
2014). To verify that ACE does not have a high aﬃnity for BK-
Arg, we performed a competition assay involving [3H]enalaprilat
binding to recombinant ACE (Figure 5C). While micromolar
concentration levels of BK displace the radioligand from the
peptidase, as previously reported, BK-Arg at 10 µM had little
eﬀect in this competition assay (Figure 5C; extrapolated relative
potency of 9.6% compared with that of BK, Table 1). Whereas
pretreatment with enalaprilat did not aﬀect the hypotensive
response to 0.025 to 1.6 µg/kg BK-Arg, the pretreatment was
found to signiﬁcantly potentiate the hypotensive response elicited
by the highest dose of BK-Arg (6.4 µg/kg; P < 0.01, Dunnett’s
test). This might result from the potentiation of regenerated BK,
considering that BK-Arg has a low intrinsic aﬃnity for ACE
(Table 1; Figure 5C). Tachycardia accompanied the hypotensive
responses at doses of 0.1 to 6.4 µg/kg (P < 0.01, Dunnett’s test,
Figure 3).
Figures 6A,B shows that BK-His-Leu (0.025–6.4 µg/kg)
decreased MAP in a signiﬁcant and dose-dependent manner.
The reductions in MAP were signiﬁcant at doses of 0.4 to
6.4 µg/kg (P < 0.01, Dunnett’s test) when compared to
vehicle values. BK-His-Leu is predicted to be an indirect
activator of the B2R, via its conversion to BK, which should
involve the carboxydipeptidase ACE (Figure 1). Surprisingly,
the dose-dependent hypotensive response to BK-His-Leu, which
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FIGURE 2 | Continued
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FIGURE 2 | Continued
Hypotensive responses to i.v. bolus injections of increasing doses of bradykinin (BK) and des-Arg9-BK in anesthetized rats. (A,B) Representative traces
showing the dose-response effect of BK on systemic blood pressure in untreated rats (A) and in rats pretreated with enalaprilat (B). Enalaprilat (0.1 mg/kg) was i.v
given as bolus 15 min before starting the injections of BK. Doses of BK are in ng/kg. Abscissa: time; ordinate: arterial pressure (mm Hg). (C) Effect of i.v.
pretreatment with enalaprilat (0.1 mg/kg), icatibant (10 µg/kg), Plummer’s inhibitor (0.75 mg/kg) or B-9858 (20 µg/kg) on the maximal hypotensive response to i.v.
injections of increasing doses of BK. The pretreatment with each peptidase inhibitor was given as bolus 15 min before starting the injections of BK. The number of
determination in different animals is given between parentheses for control and each inhibitor. (D) Dose-effect for the maximal hypotensive response to des-Arg9-BK
(n = 9). Abscissa: dose (ng/kg); ordinate: fall of mean arterial blood pressure (MAP; mm Hg). Values are means ± SEM, shown by vertical lines. ∗P < 0.05;
∗∗P < 0.01 control group values compared with vehicle value; †P < 0.01 pretreated group values compared with the control group values (Dunnett’s test).
has very little aﬃnity for the B2R but a good one for ACE
(Table 1), was not signiﬁcantly aﬀected by pretreatment with
enalaprilat. However, the hypotensive eﬀect of BK-His-Leu was
abolished by pretreatment with icatibant (eﬀects signiﬁcantly
inferior to those of control animals in the 0.4–6.4 µg/kg dose
range, Dunnett’s test, Figure 6B), raising the possibility that in
the presence of enalaprilat, BK regeneration from BK-His-Leu
might involve unidentiﬁed peptidase(s) via alternate cleavage
rules. Tachycardia accompanied the hypotensive responses at
doses of 1.6 and 6.4 µg/kg (P < 0.01, Dunnett’s test, Figure 3).
Both pro-drug peptides BK-Arg and BK-His-Leu had a
tendency to produce prolonged hypotensive episodes with,
occasionally, a slow onset (Figures 5A and 6A); however, this
was variable and statistics on recovery half-time for hypotensive
episodes generally failed to show statistical diﬀerence from those
recorded following similar doses of BK.
BK-Ala-Pro is an alternate ACE substrate that may regenerate
BK following the action of ACE (Figure 1; Table 1). Figure 7
shows that BK-Ala-Pro decreased MAP in a dose-dependent
manner (eﬀects diﬀerent from the BSA-saline vehicle in the 0.4–
6.4 µg/kg dose range, P < 0.01 for each of these doses). While
icatibant abated the eﬀects of BK-Ala-Pro (P < 0.01 for the kinin
doses of 1.6 and 6.4µM, Dunnett’s test), enalaprilat pretreatment
unexpectedly potentiated this peptide (signiﬁcantly for doses of
0.025 and 1.6 µg/kg; P < 0.05 and 0.01, respectively; Figure 7C).
Hemodynamic Effects of Intravenous
Injection of BK and Alternate Kinin
Receptor Agonists in Rats
Figures 8A,B shows the simultaneous changes in phasic and
MAP, mean hindquarter Doppler shift (mHDS) signal and HR
induced by intravenous injections of vehicle, BK and alternate
kinin receptor agonists administered at doses producing a
sizeable hypotensive eﬀect of 15–30 mmHg. Thus, we found
that, for each tested agonist, the observed hypotensive response
coincided with a concomitant increase in the mean Doppler shift
signal and tachycardia when compared with vehicle values. The
increase in mHDS might reﬂect a change in vascular resistance
(vasodilation) redistributing ﬂow to the hindlimb muscles, as
previously shown in conscious rats (Bachelard et al., 1992a).
The amplitude of the hypotensive episodes (MAP) predicted
the maximal tachycardia and Doppler shift irrespective of the
peptide identity (r = 0.972 and 0.962, respectively, P < 0.01
for each comparison), suggesting actions mediated along a
continuum of physiological eﬀects mediated by cardiovascular
B2Rs.
DISCUSSION
Aberrant protease signaling pathways have been implicated
in several diseases, ranging from cardiovascular disorders to
cancer, making them attractive therapeutic targets in drug
development. To this end, the development of protease resistant
drugs might be very useful in order to prolong beneﬁcial
eﬀects of endogenous substances otherwise too rapidly degraded.
Protease-activated prodrugs can also be successfully exploited
to improve drug delivery to areas where protease expression
is higher than in normal tissues, and might contribute to
reduce oﬀ-target side eﬀects. Although the protective role
of kinins in the circulation is increasingly recognized, there
have been very few attempts to use BK or a derivative in
cardiovascular therapeutics. In the present study, we exploited
the distribution of ectopeptidases expressed in the vasculature
and blood plasma to examine in anesthetized rats the feasibility of
extracting hemodynamic eﬀects of the stimulation of endothelial
B2Rs using a variety of ligand design strategies that mainly
exploit their susceptibility toward vascular peptidases. The
vascular and plasmatic localization of ACE and kininase I–type
carboxypeptidases makes them ideally situated to regulate BK
activity on B2Rs of vascular tissue, thus avoiding extravascular
stimulation of these receptors (e.g., in sensory nerve terminal,
epithelia).
BK is a direct and high aﬃnity B2R agonist that is also an
eﬀective ACE substrate (Table 1). As expected, the rapid and
transient hypotensive response to systemic administration of BK
was greatly enhanced by pretreatment with an ACE inhibitor,
but extensively inhibited in the presence of a B2R antagonist,
and remained unchanged in the presence of a speciﬁc inhibitor
of arginine carboxypeptidases (Figure 2). These results further
conﬁrm the important role played by the ACE, as the main
BK-inactivating peptidase in the extracellular space (Cyr et al.,
2001). These ﬁndings are also consistent with previous claims
of a role of BK in the cardiovascular and therapeutic eﬀects of
ACE inhibitors, especially at the level of preformed and widely
expressed B2Rs (Leeb-Lundberg et al., 2005).
We then tested the eﬀects of the stable B2R agonist B-
9972. This analog integrates several substitutions that make it
resistant to extracellular and endosomal inactivation by multiple
peptidases/proteases (Bawolak et al., 2007, 2009). It is worth
mentioning that, in a rare attempt to evaluate therapeutic actions
of BK receptor agonists, it was shown that 4 weeks treatment with
the stable agonist B-9972, in a rat model of severe pulmonary
hypertension, causes reduction of pulmonary artery pressure and
right ventricular hypertrophy, via the classical vasodilator eﬀect
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FIGURE 3 | Bar graph showing maximal changes in heart rate (HR) elicited by i.v. injections of vehicle, and increasing doses of (A) BK (n = 10),
(B) B-9972 (n = 7), (C) BK-Arg (n = 11), and (D) BK-His-Leu (n = 10) in anesthetized rats. On the right side of each graph are presented typical tracings
showing the changes in HR elicited by the highest dose of the agonist tested. Abscissa: dose (µg/kg); ordinate: rises of HR (bpm). Values are means ± SEM.
∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 compared with vehicle value (Dunnett’s test).
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FIGURE 4 | Hypotensive responses to i.v. bolus injections of increasing doses of B-9972 in anesthetized rats. (A) Representative traces showing the
dose-response effect of B-9972 on systemic blood pressure. Doses of B-9972 are in ng/kg. Abscissa: time; ordinate: arterial pressure (mm Hg). (B) Effect of i.v.
pretreatment with enalaprilat (0.1 mg/kg) or icatibant (10 µg/kg) on the maximal hypotensive response to i.v. injections of increasing doses of B-9972. The
pretreatment with the peptidase inhibitors was given as bolus 15 min before starting the injections of B-9972. The number of determination in different animals is
given between parentheses for control and each inhibitor. Abscissa: dose (ng/kg); ordinate: fall of (MAP; mm Hg). Values are means ± SEM shown by vertical lines.
∗P < 0.01 control group values compared with vehicle value; †P < 0.05; ††P < 0.01 pretreated group values compared with the control group values (Dunnett’s test).
mediated by endothelial B2Rs (Taraseviciene-Stewart et al., 2005).
Here we found that, consistent with its low aﬃnity for ACE and
its direct agonist action on the B2R (Table 1), the i.v. injection
of B-9972 caused hypotensive responses that were not aﬀected
by pretreatment with enalaprilat, but signiﬁcantly reduced by
pretreatment with icatibant. Further, despite its diminished
aﬃnity for the B2R relative to BK, as judged from a binding
assay to recombinant B2R conducted at 0◦C in the presence of
peptidase inhibitors (Table 1), the analog B-9972 is a more potent
hypotensive agent than BK in vivo (lower threshold for eﬀects;
compare Figures 2C and 4B); B-9972 is nearly as potent as BK
tested in the presence of enalaprilat. Although we might have
expected that the synthetic peptide B-9972 exhibits prolonged
hypotensive eﬀects (independently of potency) as inferred from
previous studies involving infusion of B-9972 or comparably
designed peptides resistant to peptidases (Taraseviciene-Stewart
et al., 2005; Marketou et al., 2010; Potier et al., 2013), the
hypotensive episodes were brief and had similar temporal proﬁles
than those elicited by BK; except for the highest dose of B-9972,
that was associated with a longer half-recovery time than BK. It
is likely that the chosen administration route, i.v. boluses, leading
to rapid dilution in the organism, was responsible for the brief
hypotensive episodes noted with B-9972. Biphasic eﬀects of B-
9972 on HR were generally comparable to those of BK but of
higher amplitudes at highest doses and a lower dose threshold
for a signiﬁcant eﬀect (Figure 3).
Extending a recent in vitro study from this laboratory
(Charest-Morin et al., 2014), we provide further pharmacological
evidence of BK regeneration from extended BK sequences
that behave as B2R agonists following a limited proteolysis.
The basic postulate of this line of investigation is that the
prolonged peptides have negligible aﬃnity for the B2R, but can
regenerate BK according to a precise cleavage rule (Table 1;
Figure 1). Using the C-terminally extended peptide, BK-Arg, as
a potential substrate of kininase I–type carboxypeptidases, we
provided pharmacological evidence that BK-Arg behave as an
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FIGURE 5 | Hypotensive responses to i.v. bolus injections of increasing doses of BK-Arg in anesthetized rats. (A) Representative traces showing the
dose-response effect of BK-Arg on systemic blood pressure. Doses of BK-Arg are in ng/kg. Abscissa: time; ordinate: arterial pressure (mm Hg). (B) Effect of i.v.
pretreatment with enalaprilat (0.1 mg/kg), icatibant (10 µg/kg) or Plummer’s inhibitor (0.75 mg/kg) on the maximal hypotensive response to i.v. injections of
increasing doses of BK-Arg. The pretreatment with the peptidase inhibitors was given as bolus 15 min before the starting injections of BK-Arg. The number of
determination in different animals is given between parentheses for control and each inhibitor. Abscissa: dose (ng/kg); ordinate: fall of (MAP; mm Hg). Values are
means ± SEM. (C) Competition of [3H]enalaprilat (2 nM) binding to recombinant human somatic ACE by BK-Arg and BK. Results are expressed as the residual
specific binding (means ± SEM of n duplicate determinations). ∗P < 0.01 control group values compared with vehicle value;†P < 0.05; ††P < 0.01 pretreated group
values compared with the control group values (Dunnett’s test).
Arg-carboxypeptidase-activated B2R agonist, as the hypotensive
response to this analog was strongly inhibited by pretreatment
with icatibant and the Plummer’s inhibitor, a mercapto analog
of Arg (Plummer and Ryan, 1981) (Figure 5). These results
further support previous ﬁndings from this laboratory showing
a loss of BK-Arg contractile potency in a venous contractile
bioassay in the presence of the Plummer’s inhibitor (Charest-
Morin et al., 2014). Interestingly, the hypotensive response
Frontiers in Pharmacology | www.frontiersin.org 10 January 2016 | Volume 6 | Article 306
Jean et al. Bradykinin B2 Receptor Agonist Peptides
FIGURE 6 | Hypotensive responses to i.v. bolus injections of increasing doses of BK-His-Leu in anesthetized rats. (A) Representative traces showing the
dose-response effect of BK-His-Leu on systemic pressure. Doses of BK-His-Leu are in ng/kg. Abscissa: time; ordinate: arterial pressure (mm Hg). (B) Effect of i.v.
pretreatment with enalaprilat (0.1 mg/kg) or icatibant (10 µg/kg) on the maximal hypotensive response to i.v. injections of increasing doses of BK-His-Leu. The
pretreatment with the peptidase inhibitors was given as bolus 15 min before starting the injections of BK-His-Leu. The number of determination in different animals is
given between parentheses for control and each inhibitor. Abscissa: dose (ng/kg); ordinate: fall of (MAP; mm Hg). Values are means ± SEM. ∗P < 0.01 control group
values compared with vehicle value; †P < 0.05; ††P < 0.01 pretreated group values compared with the control group values (Dunnett’s test).
elicited by the highest dose of BK-Arg was potentiated in
the presence of enalaprilat. Considering that BK-Arg has very
little direct aﬃnity for ACE (Table 1), it is thus plausible that
the enhanced response was consecutive to a potentiation of
regenerated BK.
Pharmacological evidence of B2R-mediated hypotensive
response to BK-His-Leu or BK-Ala-Pro, two C-terminally
extended BK peptides shown to have very little direct aﬃnity
at the B2R (Charest-Morin et al., 2014), was obtained as
icatibant abated the hypotensive eﬀect of each of these peptides.
However, in contrast to what we previously found in the
human umbilical vein contractility assay, and despite the good
aﬃnity of both peptides for ACE [Table 1; (Charest-Morin
et al., 2014)], the simple postulated cleavage rule leading to
BK regeneration following a single catalytic step mediated by
ACE was not supported. Indeed, pretreatment with enalaprilat
failed to reduce the hypotensive response of either prolonged
peptide. When ACE is blocked, the gain of function resulting
from the regeneration of BK in vivo must follow alternative
cleavage rules involving unidentiﬁed carboxypeptidase(s). In
turn, regenerated BK may be considerably potentiated by ACE
blockade, leading to such paradoxical results as a gain of
apparent potency of BK-Ala-Pro in response to enalaprilat
pretreatment (Figure 7). Therefore, BK-His-Leu and BK-Ala-Pro
are certainly pro-drugs that release BK, but in a more complex
metabolic context than that anticipated from previous in vitro
experiments.
The possible involvement of inducible B1R to the transient
hypotensive response elicited by the three C-terminally
extented analogs appears unlikely as these peptides were
shown to have little or no direct aﬃnity for the B1R (Charest-
Morin et al., 2014). Although it is not excluded that the
prodrug peptides indirectly produce small amounts of the
B1R agonist des-Arg9-BK from regenerated BK or otherwise,
we showed that the eﬀects of des-Arg9-BK were extremely
small in healthy rats (Figure 1D), in which the expression
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FIGURE 7 | Hypotensive responses to i.v. bolus injections of increasing doses of BK-Ala-Pro in anesthetized rats. (A,B) Representative traces showing
the dose-response effect of BK-Ala-Pro on systemic blood pressure in untreated rats (A) and in rats pretreated with enalaprilat (B). Enalaprilat (0.1 mg/kg) was i.v
given as bolus 15 min before starting the injections of BK-Ala-Pro. Doses of BK-Ala-Pro are in ng/kg. Abscissa: time; ordinate: arterial pressure (mm Hg). (C) Effect
of i.v. pretreatment with enalaprilat (0.1 mg/kg) or icatibant (10 µg/kg) on the maximal hypotensive response to i.v. injections of increasing doses of BK-Ala-Pro. The
pretreatment with the peptidase inhibitors was given as bolus 15 min before starting the injections of BK-Ala-Pro. The number of determination in different animals is
given between parentheses for control and each inhibitor. Abscissa: dose (ng/kg); ordinate: fall of (MAP; mm Hg). Values are means ± SEM. ∗P < 0.01 control group
values compared with vehicle value; †P < 0.05; ††P < 0.01 pretreated group values compared with the control group values (Dunnett’s test).
of inducible B1Rs should be minimal (Leeb-Lundberg et al.,
2005).
Both pro-drug peptides BK-Arg and BK-His-Leu had
a tendency to produce prolonged hypotensive episodes
with, occasionally, a slow onset, which might result from
a slow and progressive regeneration of BK following
limited proteolysis (see for instance Figure 8A). However,
this was variable and statistics on half-recovery time for
hypotensive episodes generally failed to show statistical
diﬀerence from those recorded following similar doses of
BK under the applied protocol (bolus administration of
peptides).
Using miniature pulsed Doppler ﬂow probes acutely
implanted in the experimental animals (Figure 8), we
demonstrate that the transient hypotensive response to BK
and all tested alternate kinin receptor agonists coincided with a
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FIGURE 8 | Cardiovascular responses to i.v. bolus injections of BK and three alternate kinin receptor agonists in anesthetized rats. (A) Simultaneous
changes in arterial pressure (AP), mean hindquarter Doppler shift (mHDS) signal and HR elicited by i.v. injections of BK, B-9972, BK-Arg, and BK-His-Leu. Abscissa:
time; ordinate: AP (mm Hg), mHDS (kHz); HR (beats per minute, bpm). (B) Bar graph showing maximal fall in MAP and rises in mHDS and HR elicited by i.v.
injections of vehicle, BK and the three alternate kinin receptor agonists. Abscissa: dose (ng/kg); ordinate: fall of MAP (mm Hg) and rises of mHDS (%) and HR (bpm).
Values are means ± SEM. BK (700 ng/kg), B-9972 (150 ng/kg), BK-Arg (2 µg/kg), and BK-His-Leu (400 ng/kg) were randomly administered as bolus in 10
anesthetized rats (see Materials and Methods). See Results for analysis.
concomitant increase in the mHDS signal and tachycardia. The
increase in mean Doppler shift might reﬂect a change in vascular
resistance (vasodilation) redistributing ﬂow to the hindlimb
muscles, as previously shown by one of us in conscious rats
(Bachelard et al., 1992a). These vasodilator eﬀects might likely
involve the synthesis and release of endothelial relaxing factors
after the activation of B2Rs, such as NO and prostaglandins
(Nasjletti andMalik, 1979; D’Orléans-Juste et al., 1989; Veeravalli
and Akula, 2004).
The present study constitutes an in vivo conﬁrmation of the
diﬀerential susceptibility of a set of BK analogs to peptidases,
B-9972 being totally ACE-resistant and the pro-drug BK-Arg
regenerating BK via the action of Arg-carboxypeptidase activity.
Additional pro-drug peptides, BK-His-Leu and BK-Ala-Pro, also
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regenerate BK in vivo, probably by more than one cleavage rule.
Whether peptidase-activated B2R agonists evade extra-vascular
eﬀects by progressively releasing the fragile peptide BK in the
microcirculation remains to be established. Future studies may
compare the burden of side eﬀects (e.g., plasma extravasation)
of the two general strategies, administration of a pro-peptide
that releases BK vs. the use of a peptidase-resistant agonist like
B-9972.
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